Comparison of two growth hormone stimulation tests and their cut-off limits in healthy adults at an outpatient clinic.

What Was Tested

This clinical trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone).

This cut-off is based on results obtained by polyclonal radioimmunoassays preferably under standard conditions at hospital.

Their aim was to evaluate the validity of this cut-off limit using two currently used immunometric GH assays and to compare GH responses in the ITT and the GH releasing hormone + arginine (GHRH + ARG) test in healthy adults at their outpatient endocrine unit.

Who Took Part

According to the abstract, 73 subjects were involved.

By PubMed's age tags, the people studied were young adults, adults and middle-aged adults, both men and women.

How the Study Was Run

GH was measured by an immunofluorometric and immunochemiluminometric assay.

What Was Measured

Topics PubMed links to this paper include Ambulatory Care Facilities, Arginine, Growth Hormone-Releasing Hormone, Healthy Volunteers, Human Growth Hormone and Pituitary Function Tests.

The authors tagged it with the keywords Adults, Diagnosis, GHRH+ARG, Growth hormone deficiency and ITT.

What This Means in Plain Language

This is a clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone) in 73 subjects.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2013 (Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society), a journal based in Scotland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the GHRH (Growth Hormone-Releasing Hormone) compound page, all human trials.